Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 7th. Analysts expect Infinity Pharmaceuticals to post earnings of ($0.20) per share for the quarter.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). During the same quarter in the previous year, the firm earned $1.05 EPS. On average, analysts expect Infinity Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of Infinity Pharmaceuticals, Inc. (NASDAQ INFI) opened at $2.56 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 6.29 and a current ratio of 6.29. Infinity Pharmaceuticals, Inc. has a 1-year low of $0.84 and a 1-year high of $3.84.
In related news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of the stock in a transaction on Wednesday, October 4th. The stock was bought at an average price of $1.26 per share, with a total value of $2,016,057.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.81% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Infinity Pharmaceuticals, Inc. (INFI) Scheduled to Post Earnings on Tuesday” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/06/infinity-pharmaceuticals-inc-infi-scheduled-to-post-earnings-on-tuesday.html.
Several brokerages have weighed in on INFI. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Wells Fargo & Company raised shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday, October 12th. Finally, ValuEngine lowered shares of Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
What are top analysts saying about Infinity Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Infinity Pharmaceuticals Inc. and related companies.